Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000788201 | SCV000060233 | uncertain significance | not provided | 2022-08-09 | criteria provided, single submitter | clinical testing | The p.Lys97Asn variant in TNNT2 has been previously reported in at least 4 individuals with hypertrophic cardiomyopathy (HCM) and segregated with disease in at least 4 affected relatives from two families, 3 of whom were tested in a research laboratory (Harada 2004 PMID: 15631686, Coppini 2014 PMID: 25524337, Walsh 2017 PMID: 27532257, LMM data). This variant was also identified in 1 individual with DCM and a family history of HCM (possible end-stage HCM, LMM data). This variant has also been reported in ClinVar (Variation ID 43631) and has been identified in 0.0009% (1/113760) European chromosomes in gnomAD (https://gnomad.broadinstitute.org/). In vitro functional studies provide conflicting evidence on whether this variant impacts protein function (Gangadharan 2017 PMID: 28973951, Pettinato 2020 PMID: 33025817). Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, the clinical significance of this variant is uncertain. ACMG/AMP Criteria applied: PS4_Supporting, PP1, PM2_Supporting, PP3. |
Blueprint Genetics | RCV000788201 | SCV000927237 | pathogenic | not provided | 2017-04-22 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000791922 | SCV000931191 | pathogenic | Hypertrophic cardiomyopathy 2; Dilated cardiomyopathy 1D; Cardiomyopathy, familial restrictive, 3 | 2023-10-18 | criteria provided, single submitter | clinical testing | This sequence change replaces lysine, which is basic and polar, with asparagine, which is neutral and polar, at codon 97 of the TNNT2 protein (p.Lys97Asn). This variant is present in population databases (rs397516459, gnomAD 0.0009%). This missense change has been observed in individuals with TNNT2-related conditions (PMID: 21185001, 25524337, 27532257; Invitae). ClinVar contains an entry for this variant (Variation ID: 43631). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt TNNT2 protein function. Experimental studies have shown that this missense change affects TNNT2 function (PMID: 33025817). For these reasons, this variant has been classified as Pathogenic. |
Genome- |
RCV003450691 | SCV004181475 | likely pathogenic | Dilated cardiomyopathy 1D | 2023-04-11 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV003450692 | SCV004181476 | likely pathogenic | Cardiomyopathy, familial restrictive, 3 | 2023-04-11 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV003450690 | SCV004181477 | likely pathogenic | Hypertrophic cardiomyopathy 2 | 2023-04-11 | criteria provided, single submitter | clinical testing | |
Human Genetics Bochum, |
RCV003886369 | SCV004704565 | likely pathogenic | See cases | 2023-11-13 | criteria provided, single submitter | clinical testing | ACMG criteria used to clasify this variant: PS3_MOD, PS4_MOD, PP3_MOD, PM2_SUP |
Stanford Center for Inherited Cardiovascular Disease, |
RCV000223847 | SCV000280520 | uncertain significance | not specified | 2011-12-19 | no assertion criteria provided | clinical testing | Note this variant was found in clinical genetic testing performed by one or more labs who may also submit to ClinVar. Thus any internal case data may overlap with the internal case data of other labs. The interpretation reviewed below is that of the Stanford Center for Inherited Cardiovascular Disease |